Insmed
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 912
- Market Cap
- $13.2B
- Introduction
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
- First Posted Date
- 2005-01-31
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Insmed Incorporated
- Target Recruit Count
- 19
- Registration Number
- NCT00102531
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸The Albert Einstein College of Medicine Montefiore Medical Center, New York, New York, United States
© Copyright 2025. All Rights Reserved by MedPath